Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Initially, all the children participated in a randomized, controlled GH trial, conducted to assess the effects of GH treatment on growth, body composition and behaviour.

Why It Was Studied

The attained height percentile was maintained during the continued GH treatment.

Five years after the start of GH treatment, mean height SDS is still above average for age.

Who Took Part

According to the abstract, 18 children were involved.

PubMed indexes the participants as young children, children and teenagers.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Body Height, Body Mass Index, Child Development, Glucose, Homeostasis, Human Growth Hormone and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1999 (Acta paediatrica (Oslo, Norway : 1992). Supplement), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.